Initial REMS Approval: December[removed]NDA[removed]SUBOXONE (buprenorphine and naloxone) sublingual tablet CIII

First Page		Document Content
Alcohols Morphinans Drug rehabilitation Ketones Dosage forms Buprenorphine Naloxone Opioid dependence Drug Addiction Treatment Act Chemistry Organic chemistry Pharmacology		Initial REMS Approval: December[removed]NDA[removed]SUBOXONE (buprenorphine and naloxone) sublingual tablet CIII Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 454,99 KB Share Document on Facebook

	Naloxone: Frequently Asked Questions 1. What are the side eﬀects of naloxone? Naloxone reverses opioid overdose and causes withdrawal. The most common symptoms of withdrawal are pain, nausea, vomiting, sweating, and an DocID: 1vnAY - View Document
	THE SOUTH CAROLINA BOARD OF MEDICAL EXAMINERS AND THE SOUTH CAROLINA BOARD OF PHARMACY’S JOINT PROTOCOL TO INITIATE DISPENSING OF NALOXONE HCI WITHOUT A PRESCRIPTION This joint prot DocID: 1v7GG - View Document
	This standing order authorizes any pharmacist practicing in the state of Missouri and licensed by the Missouri Board of Pharmacy to dispense or sell the following naloxone products to persons as directed below. Naloxone DocID: 1uXi5 - View Document
	LEGAL INTERVENTIONS TO INCREASE ACCESS TO NALOXONE IN KENTUCKY Fact Sheet Legal Interventions to Reduce Overdose Mortality in Kentucky DocID: 1uX5Q - View Document
	1 Grant Program for County Health Departments to Enhance Access to Naloxone The Ohio Mental Health and Addiction Services (OhioMHAS), through its Community Innovationsline item, and other resources, is commit DocID: 1uTq7 - View Document